# Feasibility Process

The Feasibility process is used to evaluate clinical trials awarded by Sponsors to determine whether they are an appropriate fit for exceptional performance at an IACT Site.

The process includes assessment of operational capabilities, trial budgets, resources needed, and the overall business value. By thoroughly vetting potential trials, IACT ensures sites are successful in study enrollment and execution. This makes IACT a brand industry leaders can trust.

## 1 Study Lead Review

A new study lead is received and reviewed by the business development team to access suitability for placement at various sites.

## 2 Confidential Disclosure Agreement (CDA) / Feasibility Questionnaire (FQ)

A CDA is a document designed to safeguard the release and exchange of a Sponsor's confidential information. An FQ is a multiple page questionnaire focused on the site's capability to successfully conduct the study. IACT completes the initial FQ with the assistance of the Site and Principal Investigator.

## 3 Pre-Study Site Visit (PSV)

If the responses in an FQ match what a Sponsor is looking for in an ideal research site, the Site will be contacted to schedule a PSV. A PSV is a meeting where a Sponsor/ CRO visits a Site to evaluate the Site's ability to carry out the study protocol and enroll a sufficient number of patients.

- When a PSV request is received, the IACT staff performs an in-depth review to ensure the site has the patients to be successful and that the PI approves of the protocol.
- During the PSV, the team fills out IACT's internal feasibility form which is a fact-finding guidance document to again ensure suitability of the study.

## 4 Feasibility Meeting

If a trial has been awarded to a Site, IACT will schedule a Feasibility Meeting with the Feasibility Team (PI, CRC, Contract/Budget, Patient Recruitment, etc.). The Team meets to determine if the trial will move forward or not based on the group's evaluation of the study.

The IACT Regulatory Department will present the study to the Integrity Panel for CRH research. Once approved, study start-up begins.